Latest news

• BeiGene’s Brukinsa misses the mark in head-to-head Imbruvica trial

  Brukinsa was unable to demonstrate statistically significant superiority in complete response (CR) or very good partial response (VGPR) rates compared to Imbruvica. ... Although, BeiGene has said that Brukinsa demonstrated numerically higher VGPR rates,

• AstraZeneca’s Calquence impresses in previously untreated CLL

  However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy  Brukinsa (zanubrutinib).

• China updates drug reimbursement list, agrees price cuts

  mantle cell lymphoma therapy Brukinsa.

• AstraZeneca wins FDA approval for Calquence in chronic lymphoma

  Also looking to extend into the lymphoma market is BeiGene, which recently won approval in the US for its MCL therapy Brukinsa (zanubrutinib).

• BeiGene bags FDA approval for first product Brukinsa in lymphoma

  China’s BeiGene has claimed its first-ever product approval in the US, getting an FDA nod for its mantle cell lymphoma (MCL) therapy Brukinsa. ... BeiGene said it will launch Brukinsa in the coming weeks, but hasn’t yet revealed its pricing plans.